Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
With economic crosswinds buffeting regional markets, income-focused investors are increasingly looking to dividend-paying equities in Asia to anchor their portfolios. We examine three prominent names offering compelling yields.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
The technology-focused lender reported solid 2025 earnings, highlighted accelerating deposit inflows and a strategic shift away from its legacy SBA portfolio. Management forecasts continued growth for 2026, banking on its digital offerings and a key securitization success.
Klarna Group confronts a wave of class action lawsuits alleging it downplayed rising loan loss risks in its buy-now-pay-later portfolio ahead of its 2025 NYSE debut. The legal challenges cast a shadow over the fintech's post-IPO performance and have sparked a broader debate about transparency in the rapidly growing BNPL sector.
A significant divestment from a short-duration bond ETF highlights a broader portfolio pivot towards growth assets as opportunity costs rise, questioning the role of capital preservation funds in a changing rate environment.
Tenet Healthcare has regained complete ownership of its revenue cycle management subsidiary Conifer, buying out CommonSpirit Health's minority stake in a deal valued at nearly $2.7 billion. The move signals Tenet's renewed commitment to the business and plans for significant AI investment.
Goldman Sachs CEO David Solomon, while optimistic on global markets, forecasts a deliberate deceleration in talent acquisition for 2026 as the bank sharpens its focus on operational efficiency and strategic resource allocation.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
Defense contractor L3Harris Technologies wins a significant U.S. Navy award to develop the Red Wolf long-range precision strike vehicle for the Marine Corps, underscoring the Pentagon's focus on advanced targeting capabilities and bolstering the company's portfolio in next-generation weapons.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
